These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 20068169

  • 1. Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.
    McCune K, Bhat-Nakshatri P, Thorat MA, Nephew KP, Badve S, Nakshatri H.
    Cancer Res; 2010 Jan 15; 70(2):685-96. PubMed ID: 20068169
    [Abstract] [Full Text] [Related]

  • 2. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
    Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.
    Horm Cancer; 2012 Aug 15; 3(4):147-59. PubMed ID: 22476979
    [Abstract] [Full Text] [Related]

  • 3. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
    Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP.
    Mol Cancer Res; 2014 Dec 15; 12(12):1829-39. PubMed ID: 25100862
    [Abstract] [Full Text] [Related]

  • 4. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
    Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, Lunet N, Schmitt F.
    Breast Cancer Res; 2009 Dec 15; 11(3):R40. PubMed ID: 19549328
    [Abstract] [Full Text] [Related]

  • 5. Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model.
    McCune K, Mehta R, Thorat MA, Badve S, Nakshatri H.
    Oncol Rep; 2010 Nov 15; 24(5):1233-9. PubMed ID: 20878115
    [Abstract] [Full Text] [Related]

  • 6. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
    Yamaguchi N, Nakayama Y, Yamaguchi N.
    J Biol Chem; 2017 May 19; 292(20):8136-8148. PubMed ID: 28270510
    [Abstract] [Full Text] [Related]

  • 7. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC.
    Int J Oncol; 2007 Feb 19; 30(2):509-20. PubMed ID: 17203234
    [Abstract] [Full Text] [Related]

  • 8. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
    Tsuboi K, Kaneko Y, Nagatomo T, Fujii R, Hanamura T, Gohno T, Yamaguchi Y, Niwa T, Hayashi SI.
    J Steroid Biochem Mol Biol; 2017 Mar 19; 167():115-125. PubMed ID: 27888136
    [Abstract] [Full Text] [Related]

  • 9. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P, Wang J, Santen RJ, Yue W.
    Cancer Res; 2007 Feb 01; 67(3):1352-60. PubMed ID: 17283173
    [Abstract] [Full Text] [Related]

  • 10. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
    Rechoum Y, Rovito D, Iacopetta D, Barone I, Andò S, Weigel NL, O'Malley BW, Brown PH, Fuqua SA.
    Breast Cancer Res Treat; 2014 Oct 01; 147(3):473-85. PubMed ID: 25178514
    [Abstract] [Full Text] [Related]

  • 11. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK, Abrahamsson A, Dabrosin C.
    Oncotarget; 2016 Aug 30; 7(35):56876-56888. PubMed ID: 27486755
    [Abstract] [Full Text] [Related]

  • 12. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.
    Endocr Relat Cancer; 2006 Dec 30; 13(4):1121-33. PubMed ID: 17158758
    [Abstract] [Full Text] [Related]

  • 13. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
    Song RX, Chen Y, Zhang Z, Bao Y, Yue W, Wang JP, Fan P, Santen RJ.
    J Steroid Biochem Mol Biol; 2010 Feb 28; 118(4-5):219-30. PubMed ID: 19815064
    [Abstract] [Full Text] [Related]

  • 14. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
    Jiang G, Wang X, Sheng D, Zhou L, Liu Y, Xu C, Liu S, Zhang J.
    Theranostics; 2019 Feb 28; 9(22):6501-6516. PubMed ID: 31588232
    [Abstract] [Full Text] [Related]

  • 15. Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.
    Traboulsi T, El Ezzy M, Dumeaux V, Audemard E, Mader S.
    Oncogene; 2019 Feb 28; 38(7):1019-1037. PubMed ID: 30190545
    [Abstract] [Full Text] [Related]

  • 16. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
    Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W.
    Cancer Res; 2016 Jul 01; 76(13):3773-84. PubMed ID: 27197147
    [Abstract] [Full Text] [Related]

  • 17. An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
    Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BW.
    Cell Res; 2014 Jul 01; 24(7):809-19. PubMed ID: 24874954
    [Abstract] [Full Text] [Related]

  • 18. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.
    Kong SL, Li G, Loh SL, Sung WK, Liu ET.
    Mol Syst Biol; 2011 Aug 30; 7():526. PubMed ID: 21878914
    [Abstract] [Full Text] [Related]

  • 19. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
    Thewes V, Simon R, Schroeter P, Schlotter M, Anzeneder T, Büttner R, Benes V, Sauter G, Burwinkel B, Nicholson RI, Sinn HP, Schneeweiss A, Deuschle U, Zapatka M, Heck S, Lichter P.
    Cancer Res; 2015 Feb 15; 75(4):720-31. PubMed ID: 25643697
    [Abstract] [Full Text] [Related]

  • 20. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
    Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema RH, Hartman J, Lykkesfeldt AE, Lam EW.
    Oncogene; 2010 May 20; 29(20):2983-95. PubMed ID: 20208560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.